JAK2 Unmutated Polycythaemia-Real-World Data of 10 Years from a Tertiary Reference Hospital.

Jalowiec, Katarzyna Aleksandra; Vrotniakaite-Bajerciene, Kristina; Jalowiec, Jakub; Frey, Noel; Capraru, Annina; Wojtovicova, Tatiana; Joncourt, Raphael; Angelillo-Scherrer, Anne; Tichelli, Andre; Porret, Naomi Azur; Rovó, Alicia (2022). JAK2 Unmutated Polycythaemia-Real-World Data of 10 Years from a Tertiary Reference Hospital. Journal of clinical medicine, 11(12), p. 3393. MDPI 10.3390/jcm11123393

[img]
Preview
Text
jcm-11-03393-v2.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

(1) Background: Polycythaemia is defined by an increase in haemoglobin (Hb) concentration, haematocrit (Hct) or red blood cell (RBC) count above the reference range adjusted to age, sex and living altitude. JAK2 unmutated polycythaemia is frequent but under-investigated in original publications. In this retrospective cohort study, we investigated the clinical and laboratory data, underlying causes, management and outcomes of JAK2 unmutated polycythaemia patients. (2) Methods: The hospital database was searched to identify JAK2 unmutated patients fulfilling WHO 2016 Hb/Hct criteria for PV (Hb >16.5 g/dL in men and >16 g/dL in women, or Hct > 49% in men and >48% in women, or RBC mass > 25% above mean normal predicted value) between 2008 and 2019. Clinical and laboratory data were collected and analysed. (3) Results: From 727,731 screened patients, 294 (0.04%) were included, the median follow-up time was 47 months. Epo and P50 showed no clear pattern in differentiating causes of polycythaemia. In 30%, the cause remained idiopathic, despite extensive work-up. Sleep apnoea was the primary cause, also in patients under 30. Around 20% had received treatment at any time, half of whom had ongoing treatment at the end of follow-up. During follow-up, 17.2% developed a thromboembolic event, of which 8.5% were venous and 8.8% arterial. The mortality was around 3%. (4) Conclusions: Testing for Epo and P50 did not significantly facilitate identification of underlying causes. The frequency of sleep apnoea stresses the need to investigate this condition. Idiopathic forms are common. A diagnostic flowchart based on our data is proposed here. NGS testing should be considered in young patients with persisting polycythaemia, irrespective of Epo and P50 levels.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Jalowiec, Katarzyna Aleksandra, Vrotniakaite-Bajerciene, Kristina, Capraru, Annina, Wojtovicova, Tatiana, Joncourt, Raphael, Angelillo, Anne, Porret, Naomi, Rovó, Alicia

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2077-0383

Publisher:

MDPI

Language:

English

Submitter:

Pubmed Import

Date Deposited:

27 Jun 2022 09:18

Last Modified:

05 Dec 2022 16:21

Publisher DOI:

10.3390/jcm11123393

PubMed ID:

35743463

Uncontrolled Keywords:

JAK2 unmutated erythrocytosis polycythaemia thrombotic risk underlying causes work-up

BORIS DOI:

10.48350/170914

URI:

https://boris.unibe.ch/id/eprint/170914

Actions (login required)

Edit item Edit item
Provide Feedback